FoxO1 as the critical target of puerarin to inhibit osteoclastogenesis and bone resorption
Journal of Pharmacy and Pharmacology · 2024
DOI: 10.1093/jpp/rgae033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2024. Verfasst von Yanling Feng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, The Second Hospital of Lanzhou University, Lanzhou 730030, China. Hauptthemen laut MEDLINE: Isoflavones, Forkhead Box Protein O1, Osteogenesis, Osteoclasts. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Lanzhou University Second Hospital.
Abstract (Originalsprache)
Background
Elevated reactive oxygen species levels promote excessive osteoclastogenesis and bone resorption. Puerarin, a natural antioxidant, can prevent bone loss through its antioxidant effects; however, the underlying molecular mechanism remains unclear. This study aimed to explore the effects of puerarin on osteoclast differentiation and bone resorption by regulating the PI3K/AKT/FoxO1 signaling pathway. Materials and methods An ovariectomized (OVX) rat model of osteoporosis and H2O2-induced oxidative cell model of RAW 264.7 cells were established. The following indices were measured including bone μ-CT scanning and the protein expression levels of FoxO1, p-FoxO1, and catalase were detected using western blotting.
Results
Puerarin strongly alleviated oxidative stress-induced bone loss in OVX rats in vivo owing to its antioxidant effects. Puerarin improved the oxidative stress status of cells and inhibited osteoclast formation in vitro. Moreover, the protein expression of FoxO1 and its downstream target, catalase, was upregulated by puerarin.
Conclusions
Puerarin improved the OPG/RANKL ratio, upregulated the protein expression and transcriptional activity of FoxO1, and suppressed the differentiation of RAW264.7 cells into osteoclasts. FoxO1 is a pivotal target of puerarin to confer anti-osteoporosis effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, The Second Hospital of Lanzhou University, Lanzhou 730030, China.
- Department of Endocrinology, The First Hospital of Lanzhou University, Lanzhou 730000, China.
ORCID-Profile: Yanling Feng
Förderung
- Lanzhou University Second Hospital
Zitieren
APA
Feng, Y., & Tang, X. (2024). FoxO1 as the critical target of puerarin to inhibit osteoclastogenesis and bone resorption. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgae033
Vancouver
Feng Y, Tang X. FoxO1 as the critical target of puerarin to inhibit osteoclastogenesis and bone resorption. Journal of Pharmacy and Pharmacology. 2024. doi:10.1093/jpp/rgae033
BibTeX
@article{Feng2024,
author = {Feng, Yanling and Tang, Xulei},
title = {FoxO1 as the critical target of puerarin to inhibit osteoclastogenesis and bone resorption},
journal = {Journal of Pharmacy and Pharmacology},
year = {2024},
doi = {10.1093/jpp/rgae033}
}
EUVIMED